Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02918006 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine
A Phase 2 study of Influenza, sponsored by Vaxart.
- Completed
- Registry status
- Phase 2
- Development phase
- 179
- Enrollment target
- 1
- Study location
NCT02918006 is a Phase 2 study of Influenza that has completed, run by Vaxart. The registered enrollment target is 179 participants, below the 36,803-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02918006, a Phase 2 study of Influenza, has completed, sponsored by Vaxart.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 179 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 2 Randomized, Placebo- and Active-Controlled, Human Influenza A/California/04/2009 (H1N1) Challenge Study Following Administration of an Oral H1N1 Hemagglutinin (HA) Adenoviral-Vector Based Seasonal Influenza Vaccine and dsRNA Adjuvant (VXA-A1.1) to Healthy Adult Volunteers.
Conditions Studied
Interventions
- OTHER Placebo Tablets
- BIOLOGICAL Fluzone®
- BIOLOGICAL VXA-A1.1
- OTHER Saline Solution for Placebo IM Injection
Study Locations (1)
California
- WCCT Global - Costa Mesa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2016-08-31 |
| Est. Completion | 2018-01-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02918006
The ClinicalTrials.gov registry entry for NCT02918006 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 179 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,803-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The listed sponsor is Vaxart, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 4 interventions - of which Placebo Tablets is the first listed.
NCT02918006 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02918006 about?
NCT02918006 is a clinical study titled "A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine". A Phase 2 Randomized, Placebo- and Active-Controlled, Human Influenza A/California/04/2009 (H1N1) Challenge Study Following Administration of an Oral H1N1 Hemagglutinin (HA) Adenoviral-Vector Based Seasonal Influenza Vaccine and dsRNA Adjuvant (VXA-A1.1) to Healthy Adult Volunteers.
What is the current status of trial NCT02918006?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 179 participants. The study started on 2016-08-31. Estimated completion is 2018-01-19.
What conditions does trial NCT02918006 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT02918006?
The interventions under investigation include: Placebo Tablets (OTHER), Fluzone® (BIOLOGICAL), VXA-A1.1 (BIOLOGICAL), Saline Solution for Placebo IM Injection (OTHER).
Who is sponsoring clinical trial NCT02918006?
This trial is sponsored by Vaxart, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02918006 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)
RECRUITING · Phase 2
-
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
RECRUITING · Phase 2
-
High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
RECRUITING · Phase 2
-
Systems Investigation of Vaccine Responses in Aging and Frailty
RECRUITING · Phase 2
-
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
RECRUITING · Phase 2
-
High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.